OverviewChartNewsTraderScreen

Soc. Generale Knock-Out AYJ/  DE000SU9QNA3  /

Frankfurt Zert./SG
6/20/2024  11:00:22 AM Chg.+0.010 Bid11:51:31 AM Ask11:51:31 AM Underlying Strike price Expiration date Option type
1.240EUR +0.81% 1.260
Bid Size: 5,000		 1.280
Ask Size: 5,000		 VALNEVA SE EO... 1.922 EUR 12/31/2078 Call
GlobeNewswire 6/5 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...
GlobeNewswire 6/4 Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
GlobeNewswire 6/3 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 5/31 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GlobeNewswire 5/21 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GlobeNewswire 5/13 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire 5/7 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 3/26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GlobeNewswire 3/25 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire 3/21 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire 3/20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 3/18 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire 3/4 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire 2/29 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire 2/15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 2/5 Valneva Announces Sale of Priority Review Voucher for $103 Million
GlobeNewswire 1/10 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
GlobeNewswire 1/4 Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Foru...
GlobeNewswire 12/29/2023 Valneva Provides Updated 2023 Financial Guidance
GlobeNewswire 12/4/2023 Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...
GlobeNewswire 12/4/2023 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine ...
GlobeNewswire 11/27/2023 EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assess...
GlobeNewswire 11/15/2023 Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including ...
GlobeNewswire 11/13/2023 Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chik...
GlobeNewswire 11/10/2023 Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®